Two decades of off-label prescribing in children: a literature review

被引:63
|
作者
Balan, Shamala [1 ]
Hassali, Mohamed Azmi Ahmad [1 ]
Mak, Vivienne S. L. [2 ]
机构
[1] Univ Sains Malaysia, Discipline Social & Adm Pharm, Sch Pharmaceut Sci, Gelugor 11800, Penang, Malaysia
[2] Monash Univ, Ctr Med Use & Safety, Fac Pharm & Pharmaceut Sci, Melbourne, Vic, Australia
关键词
Children; Dose; Indication; Off-label; Pediatric; ADVERSE DRUG-REACTIONS; INTENSIVE-CARE-UNIT; 3 PEDIATRIC WARDS; HOSPITALIZED CHILDREN; UNLICENSED DRUGS; MEDICATION USE; EUROPEAN REGULATION; MEDICINES; PRESCRIPTION; INFORMATION;
D O I
10.1007/s12519-018-0186-y
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
BackgroundIn the past two decades, many legislative and regulatory initiatives were taken globally to improve drug use in children. However, children are still found to be prescribed with off-label drugs. This study was conducted to provide an overview of the worldwide trend in off-label prescribing in children from the year 1996 to 2016.Data sourcesThe articles published in PubMed, MEDLINE and Google Scholar were searched using text words: off-label, unlicensed, paediatric and children. Additional articles were identified by reviewing the bibliography of the retrieved articles. Full-text articles published in English which reported on the prevalence of off-label prescribing in children between January 1996 and December 2016 were included.ResultsA total of 101 studies met the inclusion criteria. Off-label prescribing definition included four main categories: age, indication, dose and route of administration. The three most common reference sources used in the studies were summary of product characteristics, national formularies and package inserts. Overall, the off-label prescribing rates in children ranged from 1.2 to 99.7%. The most common category of off-label prescribing in children was dose and age.ConclusionsThis review highlighted that off-label prescribing in children was found to be highly prevalent throughout the past two decades, persistently in the neonatal intensive care units. This suggests that besides legislative and regulatory initiatives, behavioural, knowledge aspects and efforts to integrate evidence into practice related to off-label prescribing also need to be evaluated and consolidated as part of the concerted efforts to narrow the gaps in prescribing for children.
引用
收藏
页码:528 / 540
页数:13
相关论文
共 50 条
  • [41] Off-Label Prescribing in Older Patients
    Stephen H. D. Jackson
    Paul A. F. Jansen
    Arduino A. Mangoni
    Drugs & Aging, 2012, 29 (6) : 427 - 434
  • [42] Off-label prescribing in a French hospital
    Cras, Audrey
    Marie-Agnes Conscience
    Rajzbaum, Gerald
    Louet, Agnes Lillo-Le
    Lopez, Nathalie
    Tersen, Isabelle
    Bezie, Yvonnick
    PHARMACY WORLD & SCIENCE, 2007, 29 (02): : 97 - 100
  • [43] Ongoing challenges of off-label prescribing
    Day, Richard O.
    AUSTRALIAN PRESCRIBER, 2023, 46 (04) : 86 - 89
  • [44] Off-label prescribing during pregnancy
    Rayburn, WF
    Farmer, KC
    OBSTETRICS AND GYNECOLOGY CLINICS OF NORTH AMERICA, 1997, 24 (03) : 471 - &
  • [45] Off-label prescribing in a French hospital
    Audrey Cras
    Marie-Agnès Conscience
    Gérald Rajzbaum
    Agnès Lillo-Le Louët
    Nathalie Lopez
    Isabelle Tersen
    Yvonnick Bezie
    Pharmacy World & Science, 2007, 29 : 97 - 100
  • [46] Off-Label Prescribing in Pediatric Outpatients
    Palmaro, Aurore
    Bissuel, Raphael
    Renaud, Nicholas
    Durrieu, Genevieve
    Escourrou, Brigitte
    Oustric, Stephane
    Montastruc, Jean-Louis
    Lapeyre-Mestre, Maryse
    PEDIATRICS, 2015, 135 (01) : 49 - 58
  • [47] Off-label prescribing: a matter of trust
    Susan J. Allison
    Nature Reviews Nephrology, 2010, 6 : 441 - 441
  • [48] Off-label prescribing - Legal implications
    Henry, V
    JOURNAL OF LEGAL MEDICINE, 1999, 20 (03) : 365 - 383
  • [49] Off-label prescribing to children in primary care: retrospective observational study
    Suzie Ekins-Daukes
    Peter J. Helms
    Colin R. Simpson
    Michael W. Taylor
    James S. McLay
    European Journal of Clinical Pharmacology, 2004, 60 : 349 - 353
  • [50] Off-label prescribing and dose calculation discrepancies with omalizumab in children.
    Warrier, I.
    Secord, E. A.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2007, 98 (01) : A80 - A81